Agios Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	54.03	36.5	26.82	14.24	-
Revenue Growth (YoY)	48.03%	36.07%	88.36%	-	-
Cost of Revenue	6.35	4.17	2.88	1.7	-
Gross Profit	47.68	32.33	23.94	12.54	-
Selling, General & Admin	180.28	156.78	119.9	121.67	121.45
Research & Development	339.54	301.29	295.53	279.91	256.97
Total Operating Expenses	519.82	458.07	415.43	401.58	378.42
Operating Income	-472.13	-425.74	-391.49	-389.05	-378.42
Interest Income	56.38	48.08	33.34	12.79	0.84
Other Non-Operating Income (Expense)	1.96	1,096	6.06	144.45	21.07
Total Non-Operating Income (Expense)	58.34	1,144	39.4	157.25	21.91
Pretax Income	-413.8	717.97	-352.09	-231.8	-356.51
Provision for Income Taxes	-1.02	44.24	-	-	-
Net Income	-412.78	673.73	-352.09	-231.8	1,605
Earnings From Discontinued Operations	-	-	-	-	1,961
Net Income to Common	-412.78	673.73	-352.09	-231.8	1,605
Shares Outstanding (Basic)	58	57	56	55	60
Shares Outstanding (Diluted)	58	58	56	55	60
Shares Change (YoY)	0.14%	4.02%	1.57%	-9.36%	-12.39%
EPS (Basic)	-7.12	11.86	-6.33	-4.23	26.55
EPS (Diluted)	-7.12	11.64	-6.33	-4.23	26.55
Free Cash Flow	-377.29	-391.53	-297.06	-314.36	-407.32
Free Cash Flow Per Share	-6.51	-6.76	-5.34	-5.74	-6.74
Gross Margin	88.26%	88.59%	89.26%	88.03%	-
Operating Margin	-873.87%	-1166.47%	-1459.52%	-2732.07%	-
Profit Margin	-764.01%	1845.92%	-1312.63%	-1627.82%	-
FCF Margin	-698.33%	-1072.73%	-1107.49%	-2207.58%	-
EBITDA	-466.96	-420.08	-384.86	-380.48	-369.18
EBITDA Margin	-864.28%	-1150.98%	-1434.83%	-2671.93%	-
EBIT	-472.13	-425.74	-391.49	-389.05	-378.42
EBIT Margin	-873.87%	-1166.47%	-1459.52%	-2732.07%	-
Effective Tax Rate	0.25%	6.16%	0.00%	0.00%	0.00%

Updated Feb 12, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q